PHAR (Pharming Group NV) Net Profit

PHAR (Pharming Group) - company brandmark

This daily price chart on the GURU.Markets platform illustrates the performance of Pharming Group N.V. (PHAR), which develops unique therapies for rare immune pathologies and generates high profits due to a lack of competition. The current metric stands at 0.02, supported by the global market expansion of its flagship drugs. The company's capital is formed through insurance payments for the lifelong treatment of patients with hereditary angioedema.

PHAR (Pharming Group N.V.) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Pharming Group (PHAR)

- price and consensus price forecast:
Stock Quotes Pharming Corp|PHAR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pharming Corp|PHAR - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pharming Group|PHAR - Book Capitalization|Market Capitalization to Book Value pharming.com|PHAR - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Pharming Group N.V.|PHAR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Pharming Group NV|PHAR - Company Total Debt|Debts to Book Capitalization Pharming Corp|PHAR - Company Long-Term Debt|Company Short-Term Indebtedness Pharming Group|Immediate Liquidity pharming.com
- net income and valuation multiples indicators:
PHAR - Company Net Income
Summary company analysis:Pharming Group N.V.
Core merchandise of Pharming

Investors verify issuer reliability by comparing cash flows to market capitalization. This metric measures daily net profit in the US market, separating the fundamental trend from volatility. By analyzing the consolidated earnings of Pharming Group N.V. (PHAR), one can assess the risk of overpaying for current yields. Growth in this indicator confirms the efficiency of bottling line robotization and bioreactor automation at Pharming Group N.V. (PHAR). The stable trajectory of this chart indicates the successful scaling of drug production.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|Profit After Tax NKTR|UPB: Net Profit|zenasbio.com - Final Profit|IMNM (Immunome) - Net Profit|Net Profit Gossamer Bio Inc|Company Net Income KalVista Pharmaceuticals Inc (KALV)|SEPN (Septerna Pharma) - Final Profit|Company Net Income Pieris Pharmaceuticals PVLA|SVRA - Net Income|Rigel Pharmaceuticals, Inc. - Net Profit|Net Financial Result AnaptysBio Inc ANAB|Astria Pharma (ATXS) - Company Net Income|Company Profit ENGN|RAPT (RAPT Therapeutics, Inc.) - Net Profit|JBIO - Annual Net Income|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Annual Net Income Cabaletta Bio Inc|VTYX - Company Net Income|Final Profit THTX (theratech.com)|Avalo Therapeutics (AVTX) - Company Net Income|Company Net Income Eledon Pharmaceuticals Inc. (ELDN)|Net Income AGEN|Net Profit Climb Bio, Inc|Company Net Income Zura Bio Limited (ZURA)|ATYR: Profit After Tax|Adagene Inc. - Net Income|Final Profit IMA|STTK - Company Net Income|EQ (Equillium, Inc.) - Company Profit|CNTB (connectbiopharm.com) - Net Income|IMUX - Net Financial Result|Net Income ATRA|Company Net Income IFRX|Net Income XFOR (X4 Pharma)|Net Financial Result adicetbio.com|Company Net Income Celularity CELU|INMB (inmunebio.com) - Profit After Tax|Barinthus Biotherapeutics plc - Net Profit|Final Profit KZR (Kezar Life Sciences Inc.)|SABS: Net Profit|Akari Therapeutics, Plc (AKTX) - Net Profit|Company Net Income Enlivex Therapeutics Ltd|QTTB: Final Profit|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit